Navigation Links
Data Published by Researchers from The Scripps Research Institute Demonstrate Potential for MYC Inhibitor Licensed by Sorrento Therapeutics
Date:8/18/2014

division of the National Institutes of Health (NIH).

Professor Vogt, who is the EVP, CSO, & Professor at TSRI, co-discoverer of the MYC, jun, PI3K, & src oncogenes, and Sorrento's collaborator on this project, noted earlier2 that "MYC has also been called the 'emperor of oncogenes'. Targeting MYC with a small molecule inhibitor has been a daunting challenge and has given rise to the current dogma that MYC is 'undruggable'. Numerous studies have strengthened MYC's candidacy as a promising cancer drug target and also suggest that MYC inhibition might be therapeutic in many or most cancer types, irrespective of the underlying driving oncogenic mechanism. This clearly enhances the significance and importance of this potential scientific breakthrough."

"Based on its dominant role in multiple forms of cancer, it is widely acknowledged that MYC is a very important but yet unsuccessfully pursued target for cancer therapy. We are excited to have these potent and unique inhibitors in our development portfolio," said Henry Ji, Ph.D., President and Chief Executive Officer of Sorrento. "In addition, the funding from the NCI STTR grant will allow us to dedicate research support without diverting resources from other programs in our pipeline, such as the clinical development activities for Cynviloq™ and RTX."

About Sorrento Therapeutics, Inc.

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq™, the next-generation paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers
2. Newly-Published Study Confirms Stretta to be Valuable GERD Treatment
3. Newly Published Survey Shows Drug Shortages Still Have Major Impact on Patient Care
4. Romosozumab Phase 2 Data Published In New England Journal Of Medicine Show Significant Increases In Bone Mineral Density At Both Spine And Hip
5. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
6. Paper Published in American Journal of Cardiology Demonstrates Favorable Vascular Healing Following MiStent SES Implantation
7. New Findings Published In Circulation: Heart Failure Show Potential Utility Of Cardioxyls HNO Donors As Novel Treatments For Heart Failure
8. Case Report on 14-Year-Old Pediatric Patient Bridged to Transplant with SynCardia Total Artificial Heart Published in the Journal Perfusion
9. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
10. New Edition of Popular Guide to Health Economic Evaluation Published by OHE
11. Newly-Published Study Concludes Stretta May Be More Desirable GERD Treatment than Chronic PPI Use or Anti-Reflux Surgery in Some Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Breckenridge Pharmaceutical, Inc. announced today that ... with Pii (Pharmaceutics International, Inc.) ( Hunt ... Pii expect to develop and commercialize several new ... will develop, manufacture and supply the products, and ... its own label.  The drugs, comprised of four ...
(Date:11/26/2014)... 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... presentations at two upcoming investor conferences.  , 31 ... on Tuesday, December 2, 2014 at 6:45 a.m. EST / ... head of EUSA International, will provide an overview of the company ... Annual Piper Jaffray Healthcare Conference in New York, NY ...
(Date:11/26/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 3, 2014 ... Helen Torley , President and Chief Executive Officer, will provide ... through the "Investors" section of Halozyme,s corporate website at ... 90 days following the event. To access the live webcast, ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with Pharmaceutics International, Inc. 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:11/27/2014)... Today, Digital-Signage-China.com adds 2 new items to its ... signage media player promotion for Dec. 2014. , The ... wave in April, and this promotion will help to expand ... desired models on our website, she/he can contact us with ... new models come in the latest designs, and they actually ...
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) announced ... honor of World AIDS Day 2014. On Nov. 25, ASCP ... icon and infographic designed to generate public awareness about World ... , ASCP has asked members to replace their Facebook, Twitter, ... Tested. Find a cure.” icon and share the accompanying infographic ...
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number 10 ... the 50 fastest-growing technology companies in the UK. Rankings ... years. Cambrionix Ltd grew 2989 percent during this period. ... of Cambridgeshire and East and first in the sector of ... recognition of the hard work put in by our team ...
(Date:11/27/2014)... York (PRWEB) November 27, 2014 ... have been filed in a consolidated litigation now ... reports. , Documents recently updated in the ... included in the state proceeding, all of which ... disorder and other psychiatric conditions. Many of the ...
(Date:11/27/2014)... PA (PRWEB) November 27, 2014 In order ... inventor from Sharpes, Fla., designed an easy way to avoid ... it/them. , He then created a prototype of the patent-pending ... or lower a toilet seat and/or lid in a more ... prevents the spread of germs. Overall, it promotes good hygiene ...
Breaking Medicine News(10 mins):Health News:Digital-Signage-China.com Offers Big Discounts On Its New Digital Signage Media Players 2Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4
... all think we know a lot about vitamins, minerals ... studies have created confusion regarding their importance; a simple ... is that “Vitamins and other nutrients, including calcium and ... ,Stressing the point is Dr. Joseph C. Maroon, ...
... forefront of the mission to translate discoveries in basic sciences ... schools to have been chosen to receive a collective grant ... ,"The gap between basic biology and medical practice is ... education at the School of Medicine and principal investigator of ...
... in Russia has been witness to the death of more ... has hit the south of Russia.// ,According to ... Jan 25 and Feb 1, almost 350,000 birds have died ... 76,000 at the Makhachkalinskaya farm between Feb. 6 and Feb. ...
... response of MPs in favor of the proposed smoking ban in ... would be imposed by the summer of next year in the ... 184 has been achieved when the issue of smoking ban extension ... Following implementation of the law, both the public and club/pub workers ...
... mammalian protein called Rad9 could hold the key to killing ... at Washington University School of Medicine in St. Louis. Rad9 ... DNA, but it is now fund to be a "repairman" ... ,That is why reserachers are now ...
... the world's most common liver infection. It spreads easily and ... ,It causes liver cirrhosis, // liver failure and liver ... of the world's population, has been infected with the hepatitis ... are chronic carriers of the virus. Normally in case of ...
Cached Medicine News:Health News:Never undermine the importance of calcium and Vitamin D 2Health News:Getting Basic Science to Work For Medicine 2Health News:Switching Off Protein Could Play Key Role In Success Of Radiation Therapy For Cancer 2
Classic black cast boot with unisex styling...
... cast boot specially lasted for fiberglass ... rocker sole for easy ambulation! ,The ... narrow last so it fits better ... and with our stretchable upper, a ...
The Multi-Purpose Medical-Surgical Shoe...
The Low Profile boot provides a durable canvas upper, with an open toe and heel. Padded EVA insole protection. The lower outsole compensates for casting thickness. Available in six unisex sizes....
Medicine Products: